<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00250874</url>
  </required_header>
  <id_info>
    <org_study_id>Myocet 008 (L017)</org_study_id>
    <nct_id>NCT00250874</nct_id>
  </id_info>
  <brief_title>Myocet, Docetaxel &amp; Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer</brief_title>
  <official_title>Phase I-II Study of Liposomal Doxorubicin (Myocet®), Docetaxel and Trastuzumab as First-Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeneus Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeneus Pharma</source>
  <brief_summary>
    <textblock>
      To study the pharmacokinetic profile of the therapeutic schedule in order to demonstrate
      absence of negative interactions among the 3 drugs administered
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To assess the maximum tolerated dose (MTD) of Myocet at different dosages in combination
           with Taxotere at the fixed dose of 35 mg/m2 on day 2 and 9 every 21 days and weekly
           Herceptin as first line therapy in patients affected by HER-2/neu positive metastatic
           breast cancer

        2. To enhance the proportion of complete remission

        3. To allow the feasibility of the combination of Herceptin with both Myocet and Taxotere
           without an enhanced risk of cardiotoxicity
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>45</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HER-2/neu overexpression assessed by FISH test or with immunohistochemical methods:
             Dako(the result must be 3+ with dakotest); if the immunohistochemical test results 2+
             it is needed a positive FISH test

          -  Female &lt; 70yrs

          -  Histologically or cytologically proven breast cancer.

          -  Metastatic or locally advanced breast cancer (clinical stage: III-IV)

          -  Adequate hematological, hepatic, renal and cardiac function, the latter confirmed by
             echocardiography with FEVS ≥50%

          -  Prior adjuvant chemotherapy if doxorubicin total dose ≤300 mg/m2, epirubicin total
             dose ≤450 mg/m2

        Exclusion Criteria:

          -  History of cardiopathy

          -  Severe hepatic and renal diseases

          -  Brain metastases as the only parameter of disease

          -  Contraindication to the use of corticosteroids as premedication

          -  Acute infectious diseases

          -  Insulin-dependent diabetes

          -  History of other cancers except for adequately treated basal cell skin cancer or in
             situ carcinoma of the cervix

          -  Concurrent treatment with any other cancer therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Amadori</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Pietrantoni, Forli, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor Gasparini</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Filippo Neri, Rome, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Professor Amadori</last_name>
    <phone>+39 0543 731737</phone>
    <email>segronco@ausl.fo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Professor Gasparini</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Pietrantoni</name>
      <address>
        <city>Forli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Professor Amadori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2005</study_first_submitted>
  <study_first_submitted_qc>November 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2005</study_first_posted>
  <last_update_submitted>November 7, 2005</last_update_submitted>
  <last_update_submitted_qc>November 7, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

